---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024339"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:58:26.942428+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes

## Summary
- Issued $10.93M A-1 Note (9% interest) and $10M secured B Note (5% interest) for $20M purchase price.
- $900K OID and $30K expense included; maturity 18 months from March 2, 2026.
- B Note secured by $10M deposit account and pledge of ALLR Holdings LLC; guaranteed by three subsidiaries.
- Covenants restrict additional debt, variable-rate issuances, and asset encumbrances without lender consent.
- Investor can redeem up to $250K/month starting 6 months after closing; trigger events allow 10%/5% balance increases.

## SEC filing metadata
- accession: 0001213900-26-024339
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/ea0279478-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024339
- JSON: https://secwatch.observer/filing/0001213900-26-024339.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024339.txt

## Key facts
- Debt Financings
  Allarity Therapeutics, Inc. incurred loan of $10,930,000 (A-1 Note) and $10,000,000 (B Note) with Streeterville Capital, LLC at 9.00% per annum and 5.00% per annum maturing 18 months following the date of issuance.
  - Instrument: loan
  - Principal: $10,930,000 (A-1 Note) and $10,000,000 (B Note)
  - Counterparty: Streeterville Capital, LLC
  - Rate: 9.00% per annum and 5.00% per annum
  - Maturity: 18 months following the date of issuance
  - Event: incurrence
  source text: On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000) (effective 2026-03-02).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Streeterville Capital, LLC
  - Value: $20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000)
  - Effective: 2026-03-02
  source text: On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.